Rafferty Asset Management Trims Incyte Corporation Stake

Institutional investor reduces holding in biopharmaceutical company by nearly 29%

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC, an institutional investor, has trimmed its position in shares of Incyte Corporation (NASDAQ:INCY) by 28.8% during the third quarter, according to a recent SEC filing. The firm now owns 111,537 shares of the biopharmaceutical company's stock, down from 156,610 shares previously.

Why it matters

Institutional investors like Rafferty Asset Management play a significant role in the stock market, and changes in their holdings can impact a company's share price and trading volume. This move by Rafferty suggests a shift in their investment strategy or outlook on Incyte Corporation.

The details

According to the SEC filing, Rafferty Asset Management sold 45,073 shares of Incyte Corporation during the third quarter. The firm now owns approximately 0.06% of the biopharmaceutical company's outstanding shares, valued at $9.459 million as of the most recent reporting period.

  • Rafferty Asset Management trimmed its Incyte position during the third quarter of the year.

The players

Rafferty Asset Management LLC

An institutional investor that has reduced its stake in Incyte Corporation.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

This transaction by Rafferty Asset Management suggests a potential shift in sentiment around Incyte Corporation, though the reasons behind the reduced position are not entirely clear. Investors will likely monitor Incyte's performance and any further changes in institutional ownership going forward.